April 27, 2010
Wellesley, Mass. – According to a new technical market research report, ANTIFUNGAL DRUGS: TECHNOLOGIES AND GLOBAL MARKETS (PHM029C) from BCC Research (www.bccresearch.com), the global market value for antifungal drugs was an estimated $9.8 billion in 2009, but is expected to increase to more than $11.8 billion in 2014, for a 5-year compound annual growth rate (CAGR) of 3.8%.
The largest segment in the market, the North America region, is expected to increase at a 5-year CAGR of 0.7%, from $3.9 billion in 2009 to more than $4 billion in 2014.
The second-largest segment, Europe, is expected to reach $3.7 billion in 2014. The market in 2009 is estimated to be nearly $3 billion. Thus, the 5-year CAGR is projected to be 4.4%.
The third-largest segment, Latin America and South America, is expected to increase in value from an estimated $637 million in 2009 to $949 million in 2014, for a 5-year CAGR of 8.3%.
The Asia and All Other segment will increase at a 5-year CAGR of 6.3%, from $2.3 billion in 2009 to nearly $3.2 billion in 2014.
Fungi are highly resistant microbiological eukaryotic microorganisms. In other words, they are becoming drug-resistant to the approved compounds and some therapies later in clinical development.
It is a given fact that infestations in humans, animals, plants, and the environment are on the rise, with many having lethal consequences in both the immunocompetent and the immunocompromised. As such, BCC was particularly interested in examining the antifungal market growth of developing products depicting efficacy. This report includes data regarding the market shift for those products that are now relegated to over-the-counter (OTC) status previously having only been provided by prescription, and to identify new antifungal research, development, new drug applications, and novel approaches to the market.
The focus of this report is human therapeutics, including approved therapeutics with a heavy focus on therapeutics in early development. These new molecular and biological entities are from both traditional pharmaceutical sources and include naturally derived, synthetic chemicals, biological sources, as well as the “herbal natural folk medicine” marketplace.
This study will be of significant interest to hospitals, pharmacies, pharmaceutical companies, biopharmaceutical researchers, pharmaceutical company marketing executives, contract research organizations (CROs), chemists, physicians, nurses, physician assistants, pharmaceutical directors, product managers and representatives, all manner of institutional directors ranging from nursing homes and schools to those in long-term-care situations, both public and private. It will also be of interest to biologists and those interested in the field of mycology.
Antifungal Drugs: Technologies and Global Markets( PHM029C )
Publish Date: Apr 2010
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.